Week 48 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in HIV-1-infected adults from the AMBER and EMERALD Phase III trials

被引：0

作者：

Lathouwers, E. ^{[1
]}

Wong, E. ^{[2
]}

Brown, K. ^{[1
]}

Baugh, B. ^{[3
]}

Ghys, A. ^{[1
]}

Jezorwski, J. ^{[3
]}

Van Landuyt, E. ^{[1
]}

Opsomer, M. ^{[1
]}

De Meyer, S. ^{[1
]}

机构：

[1] Janssen, Pharmaceut NV, Beerse, Belgium

[2] Janssen, Sci Affairs LLC, Titusville, NJ USA

[3] Janssen, Res & Dev LLC, Raritan, NJ USA

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P294

引用

页数：2

共 43 条

[1] Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
Lathouwers, Erkki
Wong, Eric Y.
Brown, Kimberley
Baugh, Bryan
Ghys, Anne
Jezorwski, John
Mohsine, El Ghazi
Van Landuyt, Erika
Opsomer, Magda
De Meyer, Sandra
De Wit, S.
Florence, E.
Vandekerckhove, L.
Vandercam, B.
Brunetta, J.
Klein, M.
Murphy, D.
Rachlis, A.
Walmsley, S.
Ajana, F.
Cotte, L.
Girard, P-M
Katlama, C.
Molina, J-M
Poizot-Martin, I
Raffi, F.
Rey, D.
Reynes, J.
Teicher, E.
Yazdanpanah, Y.
Arasteh, K.
Bickel, M.
Bogner, J.
Esser, S.
Faetkenheuer, G.
Jessen, H.
Kern, W.
Rockstroh, J.
Spinner, C.
Stellbrink, H-J
Stoehr, A.
Antinori, A.
Castelli, F.
Chirianni, A.
De Luca, A.
Di Biagio, A.
Galli, M.
Lazzarin, A.
Maggiolo, F.
Maserati, R.
[J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2020, 36 (01) : 48 - 57
[2] Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials
Lathouwers, Erkki
Weinsteiger, Shirley
Baugh, Bryan
Ghys, Anne
Jezorwski, John
Mohsine, El Ghazi
Van Landuyt, Erika
De Meyer, Sandra
[J]. JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (06) : 3985 - 3990
[3] Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in ART-naive, HIV-1-infected adults: AMBER Week 96 results
Orkin, C.
Eron, J.
Rockstroh, J.
Podzamczer, D.
Esser, S.
Vandekerckhove, L.
Van Landuyt, E.
Lathouwers, E.
Hufkens, V.
Jezorwski, J.
Opsomer, M.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
[4] Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies)
Oliver Ackaert
David McDougall
Carlos Pérez-Ruixo
Juan Jose Pérez-Ruixo
John Jezorwski
Herta M. Crauwels
[J]. The AAPS Journal, 23
[5] Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies)
Ackaert, Oliver
McDougall, David
Perez-Ruixo, Carlos
Perez-Ruixo, Juan Jose
Jezorwski, John
Crauwels, Herta M.
[J]. AAPS JOURNAL, 2021, 23 (04):
[6] Week-48 results of AMBER: phase 3, randomised, double-blind trial in antiretroviral treatment (ART)-naive HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat (DRV/c) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Gallant, J.
Orkin, C.
Molina, J-M
Negredo, E.
Antinori, A.
Mills, A.
Eron, J.
Reynes, J.
van Landuyt, E.
Hufkens, V.
Jezorwski, J.
Opsomer, M.
[J]. HIV MEDICINE, 2018, 19 : S32 - S32
[7] Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naive and -experienced, virologically-suppressed adults living with HIV-1
Huhn, Gregory D.
Wilkin, Aimee
Mussini, Cristina
Spinner, Christoph D.
Jezorwski, John
El Ghazi, Mohsine
Van Landuyt, Erika
Lathouwers, Erkki
Brown, Kimberley
Baugh, Bryan
[J]. HIV RESEARCH & CLINICAL PRACTICE, 2021, 21 (06) : 151 - 167
[8] Week 48 results of EMERALD: a Phase 3, randomised, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults
Orkin, C.
Molina, J-M
Gallant, J.
Negredo, E.
Gathe, J.
Eron, J.
van Landuyt, E.
Lathouwers, E.
Hufkens, V.
Petrovic, R.
Opsomer, M.
[J]. HIV MEDICINE, 2018, 19 : S32 - S32
[9] Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
Molina, J-M
Gallant, J.
Orkin, C.
Negredo, E.
Bhatti, L.
Gathe, J.
Van Landuyt, E.
Lathouwers, E.
Hufkens, V.
Vanveggel, S.
Opsomer, M.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 28 - 28
[10] TENOFOVIR (TFV) ALAFENAMIDE (TAF) DOSE IN THE FIRST PIBASED SINGLE TABLET REGIMEN (STR) DARUNAVIR/COBICISTAT/EMTRICITABINE/TAF (DRV/COBI/FTC/TAF; D/C/F/TAF).
Custodio, J. M.
Wei, X.
Wang, H.
Hepner, M.
Zack, J. Z.
Callebaut, C.
McCallister, S.
Miller, M.
Kearney, B. P.
Ramanathan, S.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S36 - S36

← 1 2 3 4 5 →